TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
← New search
Home›Stocks›RYAN
RYAN logo

RYAN

RYAN SPECIALTY HOLDINGS, INC.

Next earnings Jul 29, 2026 (after close) · consensus $0.62 EPS, $892M rev

Last earnings -1.4% on 2026-04-30

Buy
$42.03
▲ +7.41%
$42.03▼ -37.08%
over 1Y
L $29.27H $66.84
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+7.4%
1W+16.9%
1M+30.2%
3M+25.9%
YTD-16.3%
1Y-37.1%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Buy
Quality
C+
Valuation
Fair value
Filings
Watch
Buy
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 26 analysts
Buy

Fast-growing E&S specialty insurance distributor with strong cash flow; GAAP net income is thin but understates economics.

Revenue $2.99B · FY2025

Ryan Specialty is a leading specialty insurance distributor — a wholesale broker, MGU and program administrator focused on the excess-and-surplus (E&S) market, which management notes offers 'significantly more flexibility in terms, conditions, and rates' than the admitted market. FY2025 revenue grew 21.9% to $2.99B, continuing a strong multi-year trajectory ($1.71B in FY2022 to $2.99B now), and operating income rose 15.4% to $494M for a 16.5% operating margin. Crucially, GAAP net income of just $63.4M (-33.0%) understates the economics: under the Up-C holding structure, much of the LLC's income is allocated to non-controlling interests and absorbed by interest expense, intangible amortization and Tax Receivable Agreement obligations, so the headline net margin of 2.1% is not the right lens. Operating cash flow of $644M (+25.0%) is the better gauge of the franchise's earning power.

The growth engine is a mix of organic E&S expansion and acquisitions — FY2025 brought Velocity, USQRisk and 360 Underwriting, expanding the MGU footprint. Looking forward, the three-year Empower restructuring program (launched Q1 2026) is expected to incur ~$160M of one-time charges through 2028 but deliver ~$80M of annual savings from 2029, a meaningful margin catalyst. The balance sheet shows $3.29B of long-term debt and a 14.37x liabilities/equity ratio, but the latter is inflated by fiduciary/premium balances (current liabilities of $5.19B largely offset by current assets of $5.06B) rather than purely corporate leverage.

Is RYAN a buy? The one-page verdict, explained →

The options angle

model · matches our verdict
Bull call spread~60d expiry
  • Long call 42 @ ~3.96 est
  • Short call 46 @ ~2.41 est
debit $155max +$245max −$155BE 43.55

BUY verdict with defined risk: the short call finances part of the long one; max loss is the net debit.

Open in the calculator →

Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue—$1.71B$2.03B$2.46B$2.99B
Gross profit—————
Operating income$187M$290M$359M$428M$494M
Net income$65.9M$61.1M$61.0M$94.7M$63.4M
Diluted EPS—————
Net margin—3.6%3.0%3.9%2.1%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$14.3B
EV / EBITDA—
EV / Sales4.8
EV / FCF22.3
P / FCF17.3
PEG (trailing)—
Earnings yield0.6%
FCF yield5.8%

Quality & risk

ROIC (est.)9.8%
Free cash flow$641M
Total debt$3.35B
Net cash-$3.19B
Altman Z-Score1.15 distress
Piotroski F-Score5/7

Capital returns

Buyback yield—
Dividend yield (est.)0.6%
Shareholder yield0.6%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Reg FD disclosure2026-05-26
  2. 8-K Shareholder vote2026-05-01
  3. 10-Q Quarterly report2026-05-01
  4. 8-K Material agreement2026-04-30
  5. 8-K Earnings results2026-04-30
  6. DEF 14A Proxy statement2026-03-17
  7. 10-K Annual report2026-02-13
  8. 8-K Exit / restructuring costs2026-02-12
  9. 8-K Material event2026-02-12

Recent filings

all on EDGAR ↗
4Period ending 2026-06-112026-06-15open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-06-032026-06-04open ↗4Period ending 2026-05-282026-06-01open ↗8-KPeriod ending 2026-05-262026-05-26open ↗SCHEDULE 13G/AFiling2026-05-14open ↗SCHEDULE 13GFiling2026-05-13open ↗4Period ending 2026-05-052026-05-06open ↗4Period ending 2026-05-052026-05-06open ↗4Period ending 2026-05-052026-05-06open ↗

Quality score

C+
ValueGrowthProfitHealthMom.
ValueB
GrowthC-
ProfitabilityC+
Financial healthC+
MomentumC-
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✗Liabilities below 2× equity
29.2752-week66.39
Revenue
$2.99B
+21.9% YoY
Net margin
2.1%
ROE
9.8%
P/E
—

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$2.99B+21.9%
Net income$63.4M-33.0%
Operating income$494M+15.4%
Cash & equivalents$158M-70.7%
Total assets$10.6B+9.5%
Total liabilities$9.31B+8.9%
Stockholders' equity$648M+3.3%
Op.: 16.5%L/E: 14.37x

Frequently asked

Is RYAN SPECIALTY HOLDINGS, INC. (RYAN) a buy?
RYAN currently carries a Buy rating with 3/5 conviction, derived from its latest SEC filings. Fast-growing E&S specialty insurance distributor with strong cash flow; GAAP net income is thin but understates economics.
What is RYAN SPECIALTY HOLDINGS, INC.'s quality score?
RYAN scores 60.57191152667096/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001849253, latest 10-Q filed 2026-05-01) · EODHD · Proprietary analysis · as of 6/21/2026, 8:52:07 PM.

›About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:52 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 6 open-market buys · 0 sales

2026-06-12
Kuczinski Anthony J
Director
Buy500.00 @ $35.77$17.9K
2026-06-11
Kuczinski Anthony J
Director
Buy2.50K @ $34.83$87.1K
2026-06-10
ROGERS JOHN W JR
Director
Buy7.50K @ $35.16$264K
2026-06-05
RYAN PATRICK G
Executive Chairman
Buy120K @ $32.50$3.90M
2026-06-03
Hamilton Janice M
Chief Financial Officer
Buy6.30K @ $31.79$200K
2026-06-03
KATZ MARK STEPHEN
EVP & General Counsel
Buy3.21K @ $31.07$99.9K
2026-05-29
Bienen Henry S
Director
Gift2.70K
2026-05-28
Bienen Henry S
Director
Gift5.76K
2026-05-28
Bienen Henry S
Director
Gift5.76K

Earnings history

beat/miss · move
2026-04-30Beat +5.3% est▲ +1.56%8-K ↗
2026-02-12Miss -11.3% est▲ +6.69%8-K ↗
2025-10-30Miss -1.3% est▲ +5.95%8-K ↗
2025-07-31Miss -0.6% est▲ +1.11%8-K ↗
2025-05-01—▲ +4.26%8-K ↗
2025-02-20—▲ +7.05%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Vs tracked universe

compare →

1195 tracked peers · median

TENK Score61 vs 67
Revenue growth21.9% vs 7.5%
Net margin2.1% vs 10.0%
Return on equity9.8% vs 12.0%
P/E— vs 26.2